O	0	10	Adenovirus	Adenovirus	NN	B-NP
O	11	12	5	5	CD	I-NP
O	13	16	E1A	E1A	NN	I-NP
O	17	25	enhances	enhance	VBZ	B-VP
O	26	33	histone	histone	NN	B-NP
O	34	45	deacetylase	deacetylase	NN	I-NP
O	46	56	inhibitors	inhibitor	NNS	I-NP
O	56	57	-	-	HYPH	B-NP
O	57	64	induced	induce	VBN	I-NP
O	65	74	apoptosis	apoptosis	NN	I-NP
O	75	82	through	through	IN	B-PP
O	83	86	Egr	Egr	NN	B-NP
O	86	87	-	-	HYPH	B-NP
O	87	88	1	1	CD	I-NP
O	88	89	-	-	HYPH	I-NP
O	89	97	mediated	mediate	VBN	I-NP
O	98	101	Bim	Bim	NN	I-NP
O	102	114	upregulation	upregulation	NN	I-NP
O	114	115	.	.	.	O

O	117	124	Histone	Histone	NN	B-NP
O	125	136	deacetylase	deacetylase	NN	I-NP
O	137	147	inhibitors	inhibitor	NNS	I-NP
O	148	149	(	(	(	O
O	149	154	HDACi	HDACi	NNS	B-NP
O	154	155	)	)	)	O
O	156	159	are	be	VBP	B-VP
O	160	166	potent	potent	JJ	B-ADJP
O	167	171	anti	anti	AFX	O
O	171	172	-	-	HYPH	O
B-Cancer	172	178	cancer	cancer	NN	B-NP
O	179	185	agents	agent	NNS	I-NP
O	186	189	for	for	IN	B-PP
O	190	197	variety	variety	NN	B-NP
O	198	200	of	of	IN	B-PP
B-Cancer	201	207	cancer	cancer	NN	B-NP
O	208	213	types	type	NNS	I-NP
O	213	214	.	.	.	O

O	215	230	Suberoylanilide	Suberoylanilide	NN	B-NP
O	231	241	hydroxamic	hydroxamic	JJ	I-NP
O	242	246	acid	acid	NN	I-NP
O	247	248	(	(	(	O
O	248	252	SAHA	SAHA	NN	B-NP
O	252	253	)	)	)	O
O	254	257	has	have	VBZ	B-VP
O	258	262	been	be	VBN	I-VP
O	263	271	approved	approve	VBN	I-VP
O	272	274	as	as	IN	B-PP
O	275	276	a	a	DT	B-NP
O	277	281	drug	drug	NN	I-NP
O	282	284	to	to	TO	B-VP
O	285	290	treat	treat	VB	I-VP
B-Cancer	291	300	cutaneous	cutaneous	JJ	B-NP
I-Cancer	301	302	T	T	NN	I-NP
I-Cancer	303	307	cell	cell	NN	I-NP
I-Cancer	308	316	lymphoma	lymphoma	NN	I-NP
O	316	317	,	,	,	O
O	318	321	and	and	CC	O
O	322	325	the	the	DT	B-NP
O	326	337	combination	combination	NN	I-NP
O	338	340	of	of	IN	B-PP
O	341	346	HDACi	HDACi	NN	B-NP
O	347	350	and	and	CC	O
O	351	356	other	other	JJ	B-NP
O	357	363	agents	agent	NNS	I-NP
O	364	368	have	have	VBP	B-VP
O	369	373	been	be	VBN	I-VP
O	374	382	actively	actively	RB	I-VP
O	383	389	tested	test	VBN	I-VP
O	390	392	in	in	IN	B-PP
O	393	397	many	many	JJ	B-NP
O	398	406	clinical	clinical	JJ	I-NP
O	407	413	trials	trial	NNS	I-NP
O	413	414	.	.	.	O

O	415	425	Adenovirus	Adenovirus	NN	B-NP
O	426	427	5	5	CD	I-NP
O	428	433	early	early	JJ	I-NP
O	434	440	region	region	NN	I-NP
O	441	443	1A	1A	NN	I-NP
O	444	445	(	(	(	O
O	445	448	E1A	E1A	NN	B-NP
O	448	449	)	)	)	O
O	450	453	has	have	VBZ	B-VP
O	454	458	been	be	VBN	I-VP
O	459	464	shown	show	VBN	I-VP
O	465	467	to	to	TO	I-VP
O	468	475	exhibit	exhibit	VB	I-VP
O	476	480	high	high	JJ	B-NP
B-Cancer	481	486	tumor	tumor	NN	I-NP
O	487	497	suppressor	suppressor	NN	I-NP
O	498	506	activity	activity	NN	I-NP
O	506	507	,	,	,	O
O	508	511	and	and	CC	O
O	512	516	gene	gene	NN	B-NP
O	517	524	therapy	therapy	NN	I-NP
O	525	530	using	use	VBG	B-VP
O	531	534	E1A	E1A	NN	B-NP
O	535	538	has	have	VBZ	B-VP
O	539	543	been	be	VBN	I-VP
O	544	550	tested	test	VBN	I-VP
O	551	553	in	in	IN	B-PP
O	554	562	clinical	clinical	JJ	B-NP
O	563	569	trials	trial	NNS	I-NP
O	569	570	.	.	.	O

O	571	575	Here	Here	RB	B-ADVP
O	575	576	,	,	,	O
O	577	579	we	we	PRP	B-NP
O	580	586	showed	show	VBD	B-VP
O	587	591	that	that	IN	B-SBAR
O	592	604	proapoptotic	proapoptotic	JJ	B-NP
O	605	613	activity	activity	NN	I-NP
O	614	616	of	of	IN	B-PP
O	617	622	HDACi	HDACi	NN	B-NP
O	623	626	was	be	VBD	B-VP
O	627	635	robustly	robustly	RB	I-VP
O	636	644	enhanced	enhance	VBN	I-VP
O	645	647	by	by	IN	B-PP
O	648	651	E1A	E1A	NN	B-NP
O	652	654	in	in	IN	B-PP
B-Cell	655	663	multiple	multiple	JJ	B-NP
I-Cell	664	670	cancer	cancer	NN	I-NP
I-Cell	671	676	cells	cell	NNS	I-NP
O	676	677	,	,	,	B-PP
O	678	681	but	but	CC	I-PP
O	682	685	not	not	RB	B-PP
O	686	688	in	in	IN	I-PP
O	689	695	normal	normal	JJ	B-NP
B-Cell	696	701	cells	cell	NNS	I-NP
O	701	702	.	.	.	O

O	703	711	Moreover	Moreover	RB	B-ADVP
O	711	712	,	,	,	O
O	713	715	we	we	PRP	B-NP
O	716	722	showed	show	VBD	B-VP
O	723	727	that	that	IN	B-SBAR
O	728	739	combination	combination	NN	B-NP
O	740	742	of	of	IN	B-PP
O	743	746	E1A	E1A	NN	B-NP
O	747	751	gene	gene	NN	I-NP
O	752	759	therapy	therapy	NN	I-NP
O	760	763	and	and	CC	O
O	764	768	SAHA	SAHA	NN	B-NP
O	769	775	showed	show	VBD	B-VP
O	776	780	high	high	JJ	B-NP
O	781	792	therapeutic	therapeutic	JJ	I-NP
O	793	801	efficacy	efficacy	NN	I-NP
O	802	806	with	with	IN	B-PP
O	807	810	low	low	JJ	B-NP
O	811	819	toxicity	toxicity	NN	I-NP
O	820	822	in	in	FW	B-NP
O	823	827	vivo	vivo	FW	I-NP
B-Cancer	828	835	ovarian	ovarian	JJ	I-NP
O	836	839	and	and	CC	I-NP
B-Cancer	840	846	breast	breast	NN	I-NP
I-Cancer	847	856	xenograft	xenograft	NN	I-NP
O	857	863	models	model	NNS	I-NP
O	863	864	.	.	.	O

O	865	869	SAHA	SAHA	NN	B-NP
O	870	883	downregulated	downregulate	VBD	B-VP
O	884	887	Bcl	Bcl	NN	B-NP
O	887	888	-	-	HYPH	B-NP
O	888	890	XL	XL	NN	I-NP
O	891	894	and	and	CC	O
O	895	906	upregulated	upregulate	VBD	B-VP
O	907	919	proapoptotic	proapoptotic	JJ	B-NP
O	920	923	BH3	BH3	NN	I-NP
O	923	924	-	-	HYPH	B-VP
O	924	928	only	only	RB	B-NP
O	929	936	protein	protein	NN	I-NP
O	937	940	Bim	Bim	NNP	I-NP
O	940	941	,	,	,	O
O	942	947	whose	whose	WP$	B-NP
O	948	958	expression	expression	NN	I-NP
O	959	962	was	be	VBD	B-VP
O	963	970	further	further	RBR	I-VP
O	971	979	enhanced	enhance	VBN	I-VP
O	980	982	by	by	IN	B-PP
O	983	986	E1A	E1A	NN	B-NP
O	987	989	in	in	IN	B-PP
B-Cell	990	996	cancer	cancer	NN	B-NP
I-Cell	997	1002	cells	cell	NNS	I-NP
O	1002	1003	.	.	.	O

O	1004	1009	These	These	DT	B-NP
O	1010	1021	alterations	alteration	NNS	I-NP
O	1022	1024	of	of	IN	B-PP
O	1025	1028	Bcl	Bcl	NN	B-NP
O	1028	1029	-	-	HYPH	B-NP
O	1029	1030	2	2	CD	I-NP
O	1031	1037	family	family	NN	I-NP
O	1038	1046	proteins	protein	NNS	I-NP
O	1047	1051	were	be	VBD	B-VP
O	1052	1060	critical	critical	JJ	B-ADJP
O	1061	1064	for	for	IN	B-PP
O	1065	1074	apoptosis	apoptosis	NN	B-NP
O	1075	1082	induced	induce	VBN	B-VP
O	1083	1085	by	by	IN	B-PP
O	1086	1089	the	the	DT	B-NP
O	1090	1101	combination	combination	NN	I-NP
O	1102	1104	in	in	IN	B-PP
B-Cell	1105	1111	cancer	cancer	NN	B-NP
I-Cell	1112	1117	cells	cell	NNS	I-NP
O	1117	1118	.	.	.	O

O	1119	1123	SAHA	SAHA	NN	B-NP
O	1124	1132	enhanced	enhance	VBD	B-VP
O	1133	1144	acetylation	acetylation	NN	B-NP
O	1145	1147	of	of	IN	B-PP
O	1148	1155	histone	histone	NN	B-NP
O	1156	1158	H3	H3	NN	I-NP
O	1159	1161	in	in	IN	B-PP
O	1162	1165	Bim	Bim	NN	B-NP
O	1166	1174	promoter	promoter	NN	I-NP
O	1175	1181	region	region	NN	I-NP
O	1181	1182	,	,	,	O
O	1183	1188	while	while	IN	B-SBAR
O	1189	1192	E1A	E1A	NN	B-NP
O	1193	1204	upregulated	upregulate	VBD	B-VP
O	1205	1208	Egr	Egr	NN	B-NP
O	1208	1209	-	-	HYPH	B-NP
O	1209	1210	1	1	CD	I-NP
O	1210	1211	,	,	,	O
O	1212	1217	which	which	WDT	B-NP
O	1218	1221	was	be	VBD	B-VP
O	1222	1230	directly	directly	RB	I-VP
O	1231	1239	involved	involve	VBN	I-VP
O	1240	1242	in	in	IN	B-PP
O	1243	1246	Bim	Bim	NN	B-NP
O	1247	1262	transactivation	transactivation	NN	I-NP
O	1262	1263	.	.	.	O

O	1264	1272	Together	Together	RB	B-ADVP
O	1272	1273	,	,	,	O
O	1274	1277	our	our	PRP$	B-NP
O	1278	1285	results	result	NNS	I-NP
O	1286	1293	provide	provide	VBP	B-VP
O	1294	1297	not	not	RB	B-CONJP
O	1298	1302	only	only	RB	I-CONJP
O	1303	1304	a	a	DT	B-NP
O	1305	1310	novel	novel	JJ	I-NP
O	1311	1318	insight	insight	NN	I-NP
O	1319	1323	into	into	IN	B-PP
O	1324	1327	the	the	DT	B-NP
O	1328	1338	mechanisms	mechanism	NNS	I-NP
O	1339	1349	underlying	underlie	VBG	B-VP
O	1350	1354	anti	anti	AFX	B-NP
O	1354	1355	-	-	HYPH	I-NP
B-Cancer	1355	1360	tumor	tumor	NN	I-NP
O	1361	1369	activity	activity	NN	I-NP
O	1370	1372	of	of	IN	B-PP
O	1373	1376	E1A	E1A	NN	B-NP
O	1376	1377	,	,	,	O
O	1378	1381	but	but	CC	B-CONJP
O	1382	1386	also	also	RB	I-CONJP
O	1387	1388	a	a	DT	B-NP
O	1389	1398	rationale	rationale	NN	I-NP
O	1399	1402	for	for	IN	B-PP
O	1403	1406	the	the	DT	B-NP
O	1407	1415	combined	combine	VBN	I-NP
O	1416	1421	HDACi	HDACi	NN	I-NP
O	1422	1425	and	and	CC	I-NP
O	1426	1429	E1A	E1A	NN	I-NP
O	1430	1434	gene	gene	NN	I-NP
O	1435	1442	therapy	therapy	NN	I-NP
O	1443	1445	in	in	IN	B-PP
O	1446	1452	future	future	JJ	B-NP
O	1453	1461	clinical	clinical	JJ	I-NP
O	1462	1468	trials	trial	NNS	I-NP
O	1468	1469	.	.	.	O

